Kylie O'Keefe

Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world.

JPMorgan Investment Management, Inc. (JPMIM) is a global, SEC-registered investment advisor headquartered in New York City. The firm was founded in 2000 as the result of Chase Manhattan's purchase of Robert Fleming Holdings and the subsequent merger of Chase and JPMorgan. In January 2010, JPMorgan Investment Advisors merged into JP Morgan Investment Management. JPMIM is a subsidiary of JPMorgan Asset Management Holdings, Inc., ultimately owned by JPMorgan Chase & Co. (NYSE: JPM). The firm primarily provides investment advisory services to both US and non-US institutional and retail clients.

Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve.

Cantor Fitzgerald & Co. is the investment bank and brokerage subsidiary of CFS CF & Co. I Holdings LP, which is owned by Cantor Fitzgerald LP in the US. The firm was founded by Bernie Gerald Cantor and John Fitzgerald in 1945. Headquartered in New York City, Cantor Fitzgerald offers clients a global, multi-asset prime brokerage platform with a focus on the quality middle market.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

ImmuneRegen BioSciences, Inc. researches and develops immunomodulation to improve pulmonary function and stimulating the human immune system. The company is headquartered in Scottsdale, AZ.

Tufts Medical Center, Inc. owns and operates an academic medical center. It provides healthcare services and programs in the areas of allergy, anesthesiology, bariatric surgery, cancer, cardiology, colon and rectal, clinical nutrition, dentistry, dermatology, ENT/otolaryngology, endocrinology, diabetes and metabolism, gastroenterology, general surgery, geriatrics, hematology/oncology, hyperbaric medicine, infectious diseases, maternity, nephrology, neurology, neurosurgery, and nutrition. The firm also offers services in the areas of obstetrics and gynecology, occupational therapy, ophthalmology, orthopedics, otolaryngology, pain management, palliative care, pathology, pediatrics, physical medicine, physical therapy, plastic surgery, psychiatry, pulmonary, radiation oncology, radiology, rheumatology, speech language pathology and audiology, thoracic and transplant surgery, trauma surgery, urology, vascular surgery, wound healing, and weight and wellness. The company was founded in 1796 and is headquartered in Boston, MA.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Central New Jersey Council Boy Scouts of America provides programs, events and opportunities of a lifetime that serve to shape the lives of young men and women in Central and Northern New Jersey. The company was founded in 1995 and is headquartered in Monmouth Junction, NJ.

Arthritis Foundation provides funds research, advocacy and support services for various kinds of arthritis and related diseases. It offers programs and services including aquatic programs, information about treatment breakthroughs, exercise tips for people with the disease and pain management information. Arthritis Foundation is located in Atlanta, GA.

Founded in 2000 by John T. Moore and Edward M. Kennedy, Jr., Marwood Group LLC is a healthcare advisory and financial services firm headquartered in New York City. The firm is a subsidiary of Marwood Group & Co. USA LLC

Founded in 2012, PTC Therapeutics Ltd. is a British pharmaceutical company that develops pharmaceutical products. Part of PTC Therapeutics, Inc., the company is based in London, UK.

Build NYC Resource Corp. is an economic development agency that assists organizations and exempt facilities in accessing debt through tax-exempt bond financing for real estate capital investments. The non-profit company is based in New York, NY and has subsidiaries in the United States.

Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation.